Sorrento Therapeutics SRNE shares are trading higher after the company reported positive preliminary results for its Phase 1 study of COVI-MSC for the treatment of ICU COVID-19 patients.
Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.
Sorrento Therapeutics shares were trading up 48.22% at $15.44. The stock has a 52-week high of $19.39 and a 52-week low of $1.55.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
